Problem Solving Treatment for Diabetes in Individuals With Poor Diabetes Control
Launched by SINGAPORE EYE RESEARCH INSTITUTE · Dec 12, 2022
Trial Information
Current as of January 14, 2025
Unknown status
Keywords
ClinConnect Summary
Assuming the recent rise in obesity prevalence persists, the lifetime risk of diabetes in Singapore will almost double by 2050. Poorly controlled diabetes leads to various diabetes-related complications which may consequently require costly lifelong treatment and have a profound impact on patients' quality of life.
Based on a previous trial on problem solving therapy in people with diabetic retinopathy and significant levels of distress, the investigators have designed a cognitive-behavioural intervention which aims to teach individuals skills to cope with and solve problems related to dia...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with type 2 diabetes and at least 1 recent reading of suboptimal glycaemic control (HbA1c ≥7.0%)
- • Able to speak English and/or Mandarin
- • Singapore citizens or those with Singapore permanent residency status
- • Aged 21 years and above
- • No cognitive impairment, as assessed using the 6-item Cognitive Impairment Test (6CIT)
- • Adequate hearing with/without hearing aids to respond to normal conversation
- • Consent to participate in the sessions if randomised to the PST-D treatment arm
- Exclusion Criteria:
- • Have hearing or cognitive impairment compromising consent or study procedures
- • All recent HbA1c readings are \<7.0%
- • Uncontactable or unwilling/unable to participate in all the PST-D sessions if randomised to the PST-D group
Trial Officials
Ecosse Lamoureux, PhD
Principal Investigator
Singapore Eye Research Institute
About Singapore Eye Research Institute
The Singapore Eye Research Institute (SERI) is a leading clinical research organization dedicated to advancing the understanding and treatment of eye diseases. As a collaborative institute affiliated with the National University of Singapore and the Singapore Health Services, SERI focuses on innovative research and clinical trials that aim to improve patient outcomes in ophthalmology. With a multidisciplinary team of experts, SERI is committed to translating scientific discoveries into effective therapies and enhancing the quality of eye care through rigorous research initiatives and community engagement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials